The classic cardiovascular complication of chronic obstructive pulmonary disease (COPD) is cor
C hronic obstructive pulmonary disease (COPD), the third leading cause of death in the United States (1) , is defined by accelerated, age-related loss of lung function resulting in incompletely reversible airway obstruction (2) . Overlapping partially with COPD, pulmonary emphysema is described as airspace enlargement distal to the terminal bronchioles with destruction of their walls.
Hypoxic pulmonary vasoconstriction, hypercapnia, acidosis, and pulmonary vascular remodeling in COPD can all contribute to increased pulmonary vascular resistance and greater right ventricular (RV) afterload, resulting in cor pulmonale or RV hypertrophy and dilation (3).
Cor pulmonale was once considered common in COPD (4), with resting pulmonary hypertension seen frequently and exertional pulmonary hypertension occurring in as many as 58% of COPD patients without resting pulmonary hypertension (5), both of which contribute to increased RV mass and volume. However, the contemporary literature on cor pulmonale in COPD is limited by small sample sizes of highly selected patients, perhaps due to the difficulties in assessing the right ventricle using transthoracic echocardiography in COPD and performing cardiac catheterization in large cohorts. Some of these small studies demonstrated increased RV mass and RV dysfunction in COPD (6) , whereas others showed reduced RV size and intrathoracic blood volumes (7) (8) (9) (10) (11) (12) (13) . Hence, changes in RV structure and function in contemporary COPD remain poorly defined.
Therefore, in the MESA (Multi-Ethnic Study of Atherosclerosis) COPD study, we assessed RV morphology in COPD and emphysema in COPD patients and control subjects drawn predominantly from the general population undergoing cardiac magnetic resonance (CMR) imaging, the standard of reference for noninvasively assessing the RV. Given our previous findings showing a small right ventricle in patients with emphysema and historical autopsy studies (18) . Participants were 50 to 79 years of age with $10 pack-years of smoking and without a clinical diagnosis of coronary heart disease, heart failure, cerebrovascular disease, asthma before 45 years of age, other lung disease or cancer, previous lung resection, stages IIIb to V kidney disease, allergy to gadolinium, claustrophobia, metal in the body, pregnancy, or weight >300 lb. Recent COPD exacerbation was a temporary exclusion criterion. We selected all eligible participants at 4 sites in the MESA Lung Study (19) and oversampled participants with COPD or emphysema from the remainder of MESA and EMCAP, in addition to a small number from neither study.
Protocols were approved by the institutional review boards of the participating institutions and the National Heart, Lung, and Blood Institute. Written informed consent was obtained from all participants.
PULMONARY FUNCTION TESTING. Spirometry was conducted in accordance with American Thoracic Society/European Respiratory Society guidelines (20) before and after inhalation of albuterol. COPD was defined as a post-bronchodilator ratio of the forced expiratory volume in 1 s (FEV 1 ) to the forced vital capacity (FVC) <0.70 (2). COPD severity was classified as mild, FEV 1 $80% predicted; moderate, FEV 1 $50% to 79% predicted; and severe, FEV 1 <50% predicted (21).
EMPHYSEMA. All participants underwent full-lung CT scans on 64-slice helical scanners following the MESA-Lung/SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study) fullinspiration protocol (22) . The percentage of emphysema was defined using Apollo software (Vida Diagnostics, Coralville, Iowa) as the percentage of total voxels within the lung field that fell below À950
Hounsfield units (23) . In addition, the presence or absence of emphysema and predominant emphysema subtype was assessed visually on all CT scans by an experienced thoracic radiologist using a standardized protocol (24) blinded to other clinical information.
MAGNETIC RESONANCE IMAGING. The CMR protocol was that of the fifth examination of MESA modified to include assessment of the pulmonary vasculature (25) ; the protocol and methods for interpretation were previously reported (26, 27) . by RVEDV. Trabeculations were excluded from RV mass and included in RV volumes, as in previous large-scale studies using CMR to assess the ventricles (27) . The RV outflow tract was included in the RV volumes, and the septum was considered part of the left ventricle for this study (Online Figure 1 ). Our method of interpretation has been shown to have high intra-and inter-reader reproducibility (28) .
Pulmonary perfusion was assessed in a subset of participants (n ¼ 141) using dynamic first-pass, contrast-enhanced CMR of the thorax. Pulmonary microvascular perfusion was assessed on a coronal slice at the level of the trachea in the peripheral 2 cm of the lung, as previously described (29, 30) .
See the Online Appendix for details of other pulmonary function measures, the CT and CMR protocols, and microvascular perfusion measures.
COVARIATES. Age, sex, race/ethnicity, educational attainment, smoking status, pack-years, and medical history were self-reported. Medication use was assessed by medication inventory (31) . Height, weight, and blood pressure were measured following standardized MESA protocols (25) . Participants with a blood cotinine level >25 ng/ml, a urine level >500 ng/ml, or a self-report of current smoking were classified as current smokers. Oxygen saturation was measured with a pulse oximeter off oxygen, if used. The minimally adjusted models included age, sex, height, weight, race/ethnicity, and the cohort from which the participant was recruited. The fully adjusted models also included smoking status, packyears, hypertension, and sleep apnea (and milliamperes for the percentage of emphysema). The full models were also then adjusted for the respective LV parameters to better understand whether the associations were right ventricle specific. There were no missing covariate data except for 10 participants (3%) who did not know whether they carried a diagnosis of sleep apnea; they were assumed not to have sleep apnea.
The p values were 2-tailed with statistical significance defined as p < 0.05. Analyses were performed with SAS version 9.2 (Cary, North Carolina) and R version 2.14.1 (Vienna, Austria).
RESULTS
The study enrollment and reasons for exclusion are shown in Online Figure 2 . Of the 310 participants, 47%
had COPD: 60 with mild, 67 with moderate, and 20 with severe disease. The mean age of the participants was 67.9 AE 7.0 years, 39.7% were women, and 27.7%
were current cigarette smokers. The race/ethnic distribution was 53.2% non-Hispanic white, 26.1% African American, 14.2% Hispanic, and 6.5% Chinese American. 
Patients with COPD were more likely to be male and white and somewhat more likely to be current smokers with more pack-years ( with COPD used long-term supplemental oxygen (all of whom had severe COPD).
COPD AND THE RIGHT VENTRICLE. RVEDV was lower in patients with COPD compared with control subjects (p ¼ 0.02) in minimally adjusted models that accounted for differences in age, sex, race/ethnicity, height, weight, and cohort. Results were similar in fully adjusted models (À7.8 ml; 95% confidence interval: À15.0 to À0.5 ml; p ¼ 0.04).
Increasing severity of COPD was significantly and monotonically associated with lower RVEDV in minimally and fully adjusted models ( Table 2 ).
The decrement in RVEDV was directly related to the FEV 1 /FVC ratio ( Figure 1A) without evidence of nonlinearity, such as a J shape (p for nonlinearity ¼ 0.65).
The association of COPD severity with lower RVEDV persisted after additional adjustment for LV enddiastolic volume (Online Table 1 ) (p ¼ 0.02).
A similar association was present for RV endsystolic volume, although its significance was marginal in the fully adjusted model ( Table 1 ). There was no evidence of nonlinearity in the association of the FEV 1 /FVC ratio and RV mass ( Figure 1B) (p for nonlinearity ¼ 0.13). The ratio of RV mass to RVEDV was slightly but significantly increased in severe COPD due to reduced volume; however, RVEF was not associated with the presence or severity of COPD ( Table 2 ).
The association of RVEDV with COPD was largely PULMONARY EMPHYSEMA AND THE RIGHT VENTRICLE.
RVEDV was monotonically lower across increasing categories of percentage of emphysema on CT.
This association was significant in minimally and fully adjusted models ( Table 3, Online Table 2 Table 3 ).
The findings for percentage of emphysema and RVEDV were not sensitive to additional adjustment or subset analyses (Online Figure 4) . We found no interaction between percentage of emphysema and smoking status or race in terms of the relationship with RVEDV (p for interaction ¼ 0.78 and 0.18, respectively).
O T H E R M E A S U R E S .
Among participants with gadolinium-enhanced CMR (n ¼ 141) (Online Table 4 ), lower RVEDVs were associated with reduced pulmonary microvascular blood flow and reduced pulmonary microvascular blood volume (Online Table 5 ).
Higher diffusing capacity for carbon monoxide was associated with larger RVEDV, RV end-systolic volume, and RV stroke volume. We saw no association between lung volumes and RV parameters (Online Table 6 ). Subset analysis with only MESA and EMCAP participants showed similar results (data not shown).
For all of the models, we performed routine checks for model fit to make sure the conclusions were not based on a few "influential" subjects. These procedures provided reassurance that the models had adequate fit. Adjustment for arterial oxygen saturation by pulse oximetry did not change the results (data not shown).
DISCUSSION
Patients with COPD displayed, on average, lower RV volumes compared with control subjects in this multicenter study that used CMR to assess RV structure and function. More severe COPD was associated with lower RV volumes, but there was no consistent relationship of COPD severity with RV Kawut et al. . These studies, however, included only a few highly select patients and did not adjust for potential confounders, issues that were addressed in this study.
A previous study in the parent MESA cohort
showed that a greater percentage of emphysema in the lower two-thirds of the lungs was associated with lower RV volumes and mass, specifically in smokers, with more complicated relationships after adjustment for the respective LV measures (16) . A lower FEV 1 /FVC ratio was associated with lower RV mass after adjustment for LV mass in that study, but in the current study, increasing COPD severity was linked to increased RV mass/RVEDV ratio, suggesting increased RV afterload. However, this association was attributable to lower RVEDV in more severe COPD patients (rather than increasing RV mass), which is difficult to attribute to increased RV wall stress.
Our findings may differ from the traditional manifestation of increased RV volumes and increased RV mass in COPD for several reasons. First, we sampled participants predominantly from the general population, resulting in a sample of patients whose COPD may be less severe than those in previous studies but making the results more generalizable. Our sample size of patients with severe COPD was similar to (or larger than) those in most previous studies. While there was a suggestion of a J-shaped relationship of RV mass with COPD severity, there was no such suggestion for RVEDV or in relation to the percentage of emphysema. Hence, the disease spectrum alone does not account for these differences.
Another explanation may be the predominant COPD subphenotypes studied. Burrows et al. (14) found that COPD patients with emphysema on chest radiography were less likely to demonstrate RV hypertrophy on electrocardiography than other COPD patients, given the same pulmonary vascular resis- 
CONCLUSIONS
In the MESA COPD study, more severe COPD and emphysema on CT were associated with lower RV volumes without changes in RVEF or RV mass.
Smaller rather than larger RV size appears to be the more common RV phenotype in COPD in the U.S.
general population without overt cardiovascular disease, perhaps better termed "cor pulmonale parvus."
Future studies of COPD treatment should consider the role of this novel cardiac comorbidity. 
